Form 4: Bausch + Lomb Director Bolsters Stake with Annual RSU Grant

Thomas W. Ross Sr., a Director at Bausch + Lomb Corporation, acquired 20,338 common shares through an annual restricted share unit grant, increasing his total beneficial ownership to 60,391 shares.

Summary

• Thomas W. Ross Sr., a Director of Bausch + Lomb Corporation (BLCO), acquired 20,338 common shares on May 27, 2025.
• This acquisition was an annual grant of restricted share units (RSUs) provided under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• The RSUs were granted at a price of $0 per share, consistent with their nature as equity compensation.
• Following this transaction, Mr. Ross Sr.'s total beneficial ownership in Bausch + Lomb Corporation increased to 60,391 common shares.
• The granted RSUs are scheduled to vest immediately prior to the company's next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through a routine grant, is generally viewed positively as it increases insider ownership and aligns the director's financial interests with those of the shareholders, signaling continued commitment to the company's success.

Positives

• The acquisition of 20,338 common shares by Director Thomas W. Ross Sr. through an RSU grant enhances the alignment of management's interests with those of shareholders.
• The grant is part of the company's established 2022 Omnibus Incentive Plan, indicating a structured approach to long-term director compensation and retention.

Future Outlook

The restricted share units granted to Director Thomas W. Ross Sr. are scheduled to vest immediately prior to the next annual meeting of shareholders, indicating a future equity event that will convert these units into common shares.

Industry Context

This Form 4 filing reflects a common practice within the healthcare and pharmaceutical industry, where publicly traded companies utilize equity grants like Restricted Share Units (RSUs) as a standard component of non-employee director compensation to align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) for non-employee director compensation is a widely adopted practice across publicly traded companies, particularly within the healthcare and medical device sectors, mirroring compensation structures seen in companies such as Johnson & Johnson (JNJ) or Abbott Laboratories (ABT).
• The Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, under which these RSUs were granted, aligns with typical corporate governance frameworks designed to attract and retain qualified board members through long-term equity incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased equity ownership by a director enhances alignment between the board's interests and shareholder value.
• Employees: While this specific filing is for a director, the existence of an Omnibus Incentive Plan suggests a broader framework for equity compensation that could also benefit employees, potentially boosting morale and retention.

Next Steps

• The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares.

Key Dates

Keywords

Bausch + Lomb, BLCO, SEC Form 4, Insider Transaction, Restricted Share Units, RSU Grant, Director Compensation, Equity Incentive Plan, Share Ownership